Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion

NCT00073554 is registered in ClinicalTrials.gov with ARCA Biopharma, Inc. as lead sponsor.

NCT NCT00073554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00073554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion
Lead sponsor
ARCA Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
Not reported
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arterial occlusive diseases, peripheral vascular diseases, thrombosis